TY  - JOUR

T1  - Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial

JO  - The Lancet

UR  - https://eprints.whiterose.ac.uk/id/eprint/226796

UR  - https://doi.org/10.1016/s0140-6736(25)00262-4

PY  - 2025/05/09

AU  - Bensimon G

AU  - Leigh PN

AU  - Tree T

AU  - Malaspina A

AU  - Payan CAM

AU  - Pham H-P

AU  - Klaassen P

AU  - Shaw PJ

AU  - Al Khleifat A

AU  - Amador MDM

AU  - Attarian S et al

ED  - 

DO  - DOI: 10.1016/s0140-6736(25)00262-4

PB  - Elsevier BV

Y2  - 2025/06/08

ER  -